These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23839194)

  • 1. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
    Jensen JD; Huynh T; Cafardi J; Sami N
    J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
    [No Abstract]   [Full Text] [Related]  

  • 2. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 3. Case presentation of moderate-severe psoriasis.
    Salmhofer W
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment.
    Sánchez-Moya AI; Daudén E
    Arch Dermatol; 2012 Nov; 148(11):1332-3. PubMed ID: 23165852
    [No Abstract]   [Full Text] [Related]  

  • 5. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 7. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 9. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
    Papadavid E; Ferra D; Koumaki D; Dalamaga M; Stamou C; Theodoropoulos K; Rigopoulos D
    Dermatology; 2014; 228(2):107-11. PubMed ID: 24504077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris.
    Zaenglein AL; Shamban A; Webster G; Del Rosso J; Dover JS; Swinyer L; Stein L; Lin X; Draelos Z; Gold M; Thiboutot D
    J Drugs Dermatol; 2013 Jun; 12(6):619-25. PubMed ID: 23839176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
    Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
    J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.
    Vitiello M; Tosti A; Abuchar A; Zaiac M; Kerdel FA
    Int J Dermatol; 2013 Mar; 52(3):358-62. PubMed ID: 23330782
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs for acne, rosacea and psoriasis.
    Treat Guidel Med Lett; 2005 Jul; 3(35):49-56. PubMed ID: 15961971
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne.
    Callender VD
    J Drugs Dermatol; 2012 May; 11(5):643-8. PubMed ID: 22527435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.